Gravity Analytica

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

CYTK 11.05.2024

SERA-AI Powered Highlights

Drug:Aficamten-001 Aficamten

Drug:Omecamtiv Mecarbil-002 Omecamtiv Mecarbil

Diseases:Hypertrophic Cardiomyopathy

Diseases:Heart Failure with Reduced Ejection Fraction

Date of Upcoming Event:2024-11-16

Name of Upcoming Event:American Heart Association Scientific Sessions 2024

Full Press Release SEC Filings Our CYTK Tweets

About Gravity Analytica

Recent Filings

SOUTH SAN FRANCISCO, Calif.,Nov. 05, 2024(GLOBE NEWSWIRE) --Cytokinetics, Incorporated(Nasdaq: CYTK) today announced six upcoming presentations at the American Heart Association Scientific Sessions 2024 taking place inChicago, ILfromNovember 16, 2024-November 18, 2024.

Aficamten

Title: Modifiability of Post-Exercise Oxygen Uptake Recovery Patterns: A Substudy of the SEQUOIA-HCM TrialPresenter:Gregory D. Lewis, M.D., Jeffrey andMary Ellen Jay Chairand Section Head, Heart Failure Medical Director,Cardiopulmonary Exercise Testing Laboratory, Professor of Medicine,Harvard Medical SchoolDate:November 17, 2024Session Title: Advances in Identification and Management of Hypertrophic CardiomyopathySession Time:9:30 AM–10:55 AM CTPresentation Time:10:00 AM–10:05 AM CTLocation: Zone 2‚ Moderated Digital Poster 9

Title: Efficacy and Safety ofAficamtenin Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM TrialPresenter:Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center atOregon Health & Science UniversityDate:November 17, 2024Session Title: Cardiomyopathy MayhemSession Time:3:15 PM–4:20 PM CTPresentation Time:4:05 PM–4:10 PM CTLocation: Zone 2‚ Moderated Digital Poster 5

Title: Changes in EQ-5D-5L withAficamtenin Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM TrialPresenter:P. Christian Schulze, MD, PhD, Professor of Medicine, Chair,Department of Internal Medicine,Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Jena,GermanyDate:November 18, 2024Session Title: Cardiomyopathy Potpourri 2Session Time:1:30 PM–2:30 PM CTLocation: Zone 2

Omecamtiv Mecarbil

Title: Effect of the Cardiac Myosin ActivatorOmecamtiv Mecarbilon Risk of Ventricular Arrhythmias in Heart Failure with Reduced Ejection Fraction: the GALACTIC-HF TrialPresenter: Alberto Foà, M.D., Ph.D., Cardiologist,Brigham and Women's Hospital,Harvard Medical School,BostonDate:November 16, 2024Session Title: Bulking Up: The Latest in Hypertrophic CardiomyopathySession Time:2:50 PM–4:05 PM CTPresentation Time:2:50 PM–2:55 PM CTLocation: Zone 1‚ Moderated Digital Poster 4

Title: Efficacy and Safety ofOmecamtiv Mecarbilin Heart Failure with Reduced Ejection Fraction According to Age: the GALACTIC-HF TrialPresenter:Henri Lu, M.D., Clinical Research Fellow, Heart Failure,Harvard UniversityDate:November 18, 2024Session Title: Taking Action to Understand the Ejection FractionSession Time:10:30 AM–11:30 AM CTLocation: Zone 2

Health Economics and Outcomes Research

Title:Association of Sociodemographic Characteristics on Costsof Care in Patients with Obstructive Hypertrophic CardiomyopathyPresenter:Anjali T. Owens, M.D., Medical Director,Center for Inherited Cardiac Disease, Assistant Professor of Medicine,University of PennsylvaniaDate:November 17, 2024Session Title: Socioeconomic Insights and Innovations in Heart FailureSession Time:9:30 AM–10:55 AM CTPresentation Time:9:50 AM–9:55 AM CTLocation: Zone 2‚ Moderated Digital Poster 5

AboutCytokinetics

Cytokineticsis a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluatingaficamten,a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM),Cytokineticssubmitted an NDA foraficamtento theU.S. Food & Drug Administrationand is progressing regulatory submissions foraficamtenfor the treatment of obstructive HCM inEurope.Aficamtenis also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial ofaficamtenas monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial ofaficamtenin patients with non-obstructive HCM, CEDAR-HCM, a clinical trial ofaficamtenin a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study ofaficamtenin patients with HCM.Cytokineticsis also developingomecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally,Cytokineticsis developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct fromaficamtenfor the potential treatment of heart failure with preserved ejection fraction (HFpEF).

For additional information aboutCytokinetics, visitwww.cytokinetics.comand follow us onX,LinkedIn,FacebookandYouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and theCYTOKINETICSand C-shaped logo are registered trademarks ofCytokineticsin theU.S.and certain other countries.

Contact:CytokineticsDiane WeiserSenior Vice President, Corporate Affairs(415) 290-7757

Source: Cytokinetics, Incorporated

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com